← Repare Therapeutics Inc. (RPTX) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Repare Therapeutics Inc. (RPTX)
Pharmaceutical Preparations · market cap $114M · as of 2026-07-14
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
3
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Repare Therapeutics (RPTX) is a ~$114M market-cap pharmaceutical company with 129 employees whose lead and apparently sole disclosed asset is RP-3500 (camonsertib), a Phase 2 candidate in advanced solid tumors. Financial disclosures are sparse in the provided facts: 2024 showed $51M revenue against an $85M net loss and $116M R&D spend, implying the company is burning well in excess of any collaboration income. No upcoming catalysts are listed and no analyst coverage is on record.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| RP-3500 (camonsertib) | Phase 2 | Advanced Solid Tumor |
| RP-6306 | Phase 2 | Advanced Cancer |
| RP-3500 | Phase 2 | Solid Tumor |
Price & technical context
3-month
+35.2%
6-month
+67.7%
12-month
+117.2%
52-wk range
$0.90–$2.65
vs 50-day MA
+13.8%
vs 200-day MA
+51.8%
Realized vol
56.6%
Max drawdown
-89.3%
Daily closes through 2026-01-27. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for RPTX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.